Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE (IHA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01457430|
Recruitment Status : Completed
First Posted : October 24, 2011
Results First Posted : October 18, 2016
Last Update Posted : October 18, 2016
Massachusetts General Hospital
Shire Human Genetic Therapies, Inc.
Information provided by (Responsible Party):
Aleena Banerji, Massachusetts General Hospital
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
All adverse events were recorded and assessed out of total attacks, not total participants. There were 78 HAE attacks; 4 adverse events were identified.